- Iron deficiency focused Shield Therapeutics said that Teva Pharmaceutical Industries had filed a notice of appeal regarding a previous patent ruling.

Teva had filed a notice of appeal to the Opposition Division of the European Patent Office's decision on Shield's patent #2 668 175, which covered a 'process for preparing an iron hydroxypyrone'.

No date had been set for the hearing.

'Shield will continue to robustly defend its intellectual property and believes the Board of Appeal should uphold the first instance decision of the European Patent Office,' Shield said.

Story provided by